Laurus Labs: Business Overview & Financial Analysis
Laurus Labs Limited is an Indian pharmaceutical and biotechnology company headquartered in Visakhapatnam, Andhra Pradesh. The company operates as a research-driven generic Active Pharmaceutical Ingredient (API) manufacturer, Finished Dosage Form (FDF) producer, and Contract Development and Manufacturing Organisation (CDMO) partner. It provides chemistry and manufacturing solutions spanning human health, animal health, crop science, peptides, and advanced biologics, including cell and gene therapy. Supported by 15 manufacturing facilities, 7 R&D centres, and an international presence in the US, Europe, and Asia, the company serves global pharmaceutical innovators and generic drug manufacturers.
Business Segment Revenue Mix of Laurus Labs (FY2026)
Laurus Labs generates the majority of its operating revenue from generic APIs and finished formulations under its Affordable Medicines division, complemented by its fast-growing CDMO business.
- Affordable Medicines Division (API & Formulations) – Rs 4,733 crore (69.5%)
- Contract Development & Manufacturing Organisation (CDMO / Synthesis) – Rs 1,896 crore (27.8%)
- Bio & Other Specialty Initiatives – Rs 184 crore (2.7%)
- Total Consolidated Revenues – Rs 6,813 crore (100.0%)
The Affordable Medicines division grew 18% year-on-year in FY2026, driven by higher formulation volumes in developed markets and anti-retroviral (ARV) API dispatches. The CDMO vertical delivered 38% top-line growth, supported by commercial NCE API dispatches and clinical late-stage pipeline projects.
Consolidated Financial Performance of Laurus Labs (FY2026)
Laurus Labs recorded double-digit top-line growth, operating leverage, and net profit expansion during FY2026.
- Revenue from Operations – Rs 6,813 crore (+23.0% YoY)
- Operating EBITDA – Rs 1,826 crore (+64.0% YoY)
- Operating EBITDA Margin – 26.8% (+670 bps YoY)
- Gross Margin – 60.4% (+500 bps YoY)
- Net Profit After Tax (PAT) – Rs 889 crore (+151.0% YoY)
- Free Cash Flow (FCF) Generated – Rs 554 crore
Consolidated revenue expanded by 23% in FY2026, led by a favorable mix of high-margin CDMO projects. Operating EBITDA margins expanded by 670 basis points to 26.8% as raw material costs stabilized and operational scale improved. Strong cash conversion enabled net debt reduction alongside ongoing capital expenditure execution.
Latest Quarterly Performance of Laurus Labs (Q4 FY2026)
Laurus Labs posted steady revenue expansion and high operating margins in the fourth quarter of FY2026.
- Revenue from Operations – Rs 1,812 crore (+5.0% YoY)
- Operating EBITDA – Rs 523 crore (+10.0% YoY)
- Operating EBITDA Margin – 28.9% (+130 bps YoY)
- Gross Margin – 61.4%
- Net Profit After Tax (PAT) – Rs 279 crore
- CDMO Segment Revenue – Rs 524 crore (+14.0% YoY)
- Affordable Medicines Revenue – Rs 1,223 crore
Quarterly performance reflected continued momentum in contract synthesis dispatches and stable formulation volume growth in North America and Europe. Operating EBITDA margin touched 28.9% due to process efficiency and lower input material expenses.
Manufacturing Facilities & Portfolio Metrics of Laurus Labs (FY2026)
Laurus Labs operates globally compliant manufacturing plants and maintains a portfolio of generic filings and patents.
- Operational Manufacturing Facilities – 15 globally approved sites
- Total Installed Reactor Volume – >8,200 kL
- USFDA Drug Master Files (DMFs) Filed – 92 cumulative filings
- Commercialized API Portfolio – 90+ active APIs
- Granted Patents Portfolio – 244 approved patents (out of 352 filed)
- Regulatory Audits Passed – 132 successful inspections without critical findings
The company operates over 8,200 kL of reactor capacity across its primary manufacturing hubs in Visakhapatnam. The API product portfolio is anchored by Anti-Retroviral (ARV), Oncology, Cardiovascular (CVS), Central Nervous System (CNS), and Gastrointestinal (GI) therapies.
CDMO Pipeline & Advanced Biologics Infrastructure of Laurus Labs (FY2026)
Laurus Labs continues to scale its contract development pipeline across small molecules, animal health, and biotechnology assets.
- Active CDMO Projects – 125+ projects (Human Health, Animal Health & Crop Science)
- Annual R&D Spend Share – 5.8% of total revenue
- Focused Advanced Technologies – Peptides, Antibody-Drug Conjugates (ADCs), Fermentation, Gene Therapy
- ImmunoACT Equity Stake – Strategic partnership for CAR-T cell therapy commercialization
The CDMO division manages over 125 active projects across Phase I, II, Phase III, and commercial supply stages. Research and development expenditure reached 5.8% of sales, funding commercial peptide capabilities, fermentation scaling, and cell/gene therapy development.
Balance Sheet Ratios & Credit Rating of Laurus Labs (FY2026)
Laurus Labs maintains a conservative balance sheet structure backed by strong credit metrics and debt coverage.
- Long-Term Credit Rating – CARE AA; Stable (Reaffirmed July 2026)
- Short-Term Credit Rating – CARE A1+ (Reaffirmed July 2026)
- Debt to Equity Ratio – 0.20x
- Overall Gearing Ratio – 0.50x
- Term Debt to Gross Cash Accruals (TD/GCA) – 0.75x
- Total Outstanding Term Debt – Rs 904.85 crore
CARE Ratings reaffirmed a CARE AA; Stable rating in July 2026, citing improved operating profitability and capital structure. The debt-to-equity ratio improved to 0.20x as total term loan obligations declined to Rs 904.85 crore.
Capex Roadmap & Strategic Expansion of Laurus Labs (FY2026–FY2028)
Laurus Labs is executing a long-term capital allocation plan to expand manufacturing infrastructure and technology platforms.
- Capital Expenditure Intensity (FY2026) – 16% of annual revenues
- Vizag Capacity Projects – Large-scale API & commercial fermentation blocks
- KRKA Joint Venture Timeline – Phase-1 formulation blocks operational by mid-2027
- Primary Capex Target Areas – Peptides, Fermentation, ADCs, and Animal Health CDMO
Capital expenditure equaled 16% of sales in FY2026 to build specialized blocks for fermentation, peptides, and animal health active ingredients. Construction progresses for the joint venture formulation facility with KRKA, with commercial production scheduled to begin by mid-2027.
Management Commentary & Future Outlook of Laurus Labs (FY2026–FY2027)
Management commentary outlines strategic priorities centered on scaling contract manufacturing, expanding non-ARV APIs, and deploying biotechnologies.
- Management projects sustained double-digit top-line growth driven by late-stage CDMO project commercialization.
- Operating EBITDA margins are guided to stay in the 26%–30% band supported by high-margin CDMO product mix.
- Affordable Medicines division will focus on volume expansion in developed market formulation launches and non-ARV generic APIs.
- Fermentation and peptide infrastructure additions in Visakhapatnam will support long-term crop science and human health supply agreements.
- Management plans to keep overall gearing below 0.50x while funding capital expenditure primarily through internal cash accruals.
Sources & References
- Laurus Labs Limited Press Release & FY2026 Financial Results (April 2026)
- Laurus Labs Limited Q4 FY2026 Investor Presentation (April 2026)
- CARE Ratings Reaffirmation Rationale for Laurus Labs Limited (July 2026)
- Ticker Finology Laurus Labs Limited Page
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Disclaimer
The information presented above on Laurus Labs Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Laurus Labs Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.